PDSB
Price
$1.33
Change
+$0.06 (+4.72%)
Updated
Jul 3 closing price
Capitalization
60.79M
38 days until earnings call
RXRX
Price
$5.27
Change
+$0.06 (+1.15%)
Updated
Jul 3 closing price
Capitalization
2.14B
37 days until earnings call
Interact to see
Advertisement

PDSB vs RXRX

Header iconPDSB vs RXRX Comparison
Open Charts PDSB vs RXRXBanner chart's image
PDS Biotechnology
Price$1.33
Change+$0.06 (+4.72%)
Volume$141.46K
Capitalization60.79M
Recursion Pharmaceuticals
Price$5.27
Change+$0.06 (+1.15%)
Volume$16.58M
Capitalization2.14B
PDSB vs RXRX Comparison Chart in %
Loading...
PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PDSB vs. RXRX commentary
Jul 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PDSB is a Buy and RXRX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 06, 2025
Stock price -- (PDSB: $1.33 vs. RXRX: $5.27)
Brand notoriety: PDSB and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PDSB: 24% vs. RXRX: 65%
Market capitalization -- PDSB: $60.79M vs. RXRX: $2.14B
PDSB [@Biotechnology] is valued at $60.79M. RXRX’s [@Biotechnology] market capitalization is $2.14B. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PDSB’s FA Score shows that 0 FA rating(s) are green whileRXRX’s FA Score has 0 green FA rating(s).

  • PDSB’s FA Score: 0 green, 5 red.
  • RXRX’s FA Score: 0 green, 5 red.
According to our system of comparison, both PDSB and RXRX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PDSB’s TA Score shows that 5 TA indicator(s) are bullish while RXRX’s TA Score has 5 bullish TA indicator(s).

  • PDSB’s TA Score: 5 bullish, 5 bearish.
  • RXRX’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, RXRX is a better buy in the short-term than PDSB.

Price Growth

PDSB (@Biotechnology) experienced а -8.28% price change this week, while RXRX (@Biotechnology) price change was -2.41% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.30%. For the same industry, the average monthly price growth was +17.40%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

PDSB is expected to report earnings on Aug 13, 2025.

RXRX is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+6.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($2.14B) has a higher market cap than PDSB($60.8M). PDSB YTD gains are higher at: -18.405 vs. RXRX (-22.041). PDSB has higher annual earnings (EBITDA): -33.08M vs. RXRX (-524.77M). RXRX has more cash in the bank: 500M vs. PDSB (40M). PDSB has less debt than RXRX: PDSB (19M) vs RXRX (92.9M). RXRX has higher revenues than PDSB: RXRX (59.8M) vs PDSB (0).
PDSBRXRXPDSB / RXRX
Capitalization60.8M2.14B3%
EBITDA-33.08M-524.77M6%
Gain YTD-18.405-22.04184%
P/E RatioN/AN/A-
Revenue059.8M-
Total Cash40M500M8%
Total Debt19M92.9M20%
FUNDAMENTALS RATINGS
PDSB: Fundamental Ratings
PDSB
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
34
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
63
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
PDSBRXRX
RSI
ODDS (%)
Bullish Trend 4 days ago
77%
N/A
Stochastic
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
78%
Momentum
ODDS (%)
Bearish Trend 4 days ago
86%
Bullish Trend 4 days ago
83%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
N/A
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
89%
Bullish Trend 4 days ago
84%
Advances
ODDS (%)
Bullish Trend 4 days ago
86%
Bullish Trend 4 days ago
84%
Declines
ODDS (%)
Bearish Trend 7 days ago
88%
Bearish Trend 24 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bullish Trend 4 days ago
87%
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FEMAX11.690.09
+0.78%
First Eagle U.S. SMID Cap Opportunity A
DBOZX24.660.12
+0.49%
BNY Mellon Balanced Opportunity Z
PAFDX36.850.14
+0.38%
T. Rowe Price Equity Income Advisor
STFBX91.380.31
+0.34%
State Farm Balanced
FFGAX20.13-0.03
-0.15%
Fidelity Advisor Global Commodity Stk A

PDSB and

Correlation & Price change

A.I.dvisor indicates that over the last year, PDSB has been loosely correlated with ARCT. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if PDSB jumps, then ARCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PDSB
1D Price
Change %
PDSB100%
+4.72%
ARCT - PDSB
49%
Loosely correlated
+1.17%
RXRX - PDSB
48%
Loosely correlated
+1.15%
ATOS - PDSB
45%
Loosely correlated
+1.43%
CRNX - PDSB
44%
Loosely correlated
+1.22%
NRIX - PDSB
44%
Loosely correlated
+2.33%
More

RXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RXRX has been closely correlated with CRSP. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if RXRX jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RXRX
1D Price
Change %
RXRX100%
+1.15%
CRSP - RXRX
72%
Closely correlated
+0.97%
BEAM - RXRX
64%
Loosely correlated
+0.65%
ABSI - RXRX
63%
Loosely correlated
+2.97%
ABCL - RXRX
61%
Loosely correlated
+1.33%
PRME - RXRX
58%
Loosely correlated
+1.30%
More